IGlarLixi is named as a drug or biological intervention in 2 clinical trials in our China trial register, 1 of which is recruiting. Lead sponsors include Shanghai Zhongshan Hospital (1) and The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1). Registered phase: Phase 4. Conditions studied include Type 2 Diabetes; Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus Type 2.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07307235 | Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents (ClinicalTrials.gov ↗) Type 2 Diabetes |
Phase 4 | Recruiting |
| NCT07274644 | Effects of iGlarLixi Versus iGlar on Liver Fat Content in Patients With Type 2 Diabetes Mellitus Combined With Metabolic Dysfunction-associated Steatotic Liver Disease (ClinicalTrials.gov ↗) Metabolic Dysfunction-Associated Steatotic Liver Disease, Diabetes Mellitus Type 2 |
Phase 4 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Type 2 Diabetes | 1 |
| Metabolic Dysfunction-Associated Steatotic Liver Disease | 1 |
| Diabetes Mellitus Type 2 | 1 |
| Lead sponsor | Trials |
|---|---|
| Shanghai Zhongshan Hospital | 1 |
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 1 |
| Register | IGlarLixi trials |
|---|---|
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how IGlarLixi works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists IGlarLixi (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.